drugset / Trial / NCT02565732

Safety and Efficacy of Botulinum Toxin Type A Topical Gel for Primary Axillary Hyperhidrosis

NCT02565732 ↗

Phase 2 Completed 67 enrolled Revance Therapeutics, Inc.
RandomizedParallel-groupDouble-blindTreatment

Summary

This is a safety and efficacy study of botulinum toxin type A in subjects with primary axillary hyperhidrosis.

Timeline

Start
2015-09
Primary completion
2015-12
Completion
2016-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Botulinum toxin type A Protein / enzyme biologic — Topical